Core Viewpoint - Northeast Pharmaceutical (000597) announced that its wholly-owned subsidiary, Shenyang Shide Pharmaceutical Co., Ltd., received the Drug Registration Certificate from the National Medical Products Administration for L-Carnitine Oral Solution, which is approved for treating primary systemic carnitine deficiency and secondary carnitine deficiency due to congenital metabolic disorders [1] Group 1 - The drug L-Carnitine Oral Solution has the approval number H20253799 and is valid until March 31, 2030 [1] - The approval of L-Carnitine Oral Solution is expected to enrich the company's product pipeline [1] - This development enhances the company's market competitiveness and presents new market opportunities [1]